TET (ten-eleven-translocation) proteins are Fe(II)-and a-ketoglutarate-dependent dioxygenases [1] [2] [3] that modify the methylation status of DNA by successively oxidizing 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxycytosine 1, [3] [4] [5] , potential intermediates in the active erasure of DNA-methylation marks 5, 6 . Here we show that IDAX (also known as CXXC4), a reported inhibitor of Wnt signalling 7 that has been implicated in malignant renal cell carcinoma 8 and colonic villous adenoma 9 , regulates TET2 protein expression. IDAX was originally encoded within an ancestral TET2 gene that underwent a chromosomal gene inversion during evolution, thus separating the TET2 CXXC domain from the catalytic domain. The IDAX CXXC domain binds DNA sequences containing unmethylated CpG dinucleotides, localizes to promoters and CpG islands in genomic DNA and interacts directly with the catalytic domain of TET2. Unexpectedly, IDAX expression results in caspase activation and TET2 protein downregulation, in a manner that depends on DNA binding through the IDAX CXXC domain, suggesting that IDAX recruits TET2 to DNA before degradation. IDAX depletion prevents TET2 downregulation in differentiating mouse embryonic stem cells, and short hairpin RNA against IDAX increases TET2 protein expression in the human monocytic cell line U937. Notably, we find that the expression and activity of TET3 is also regulated through its CXXC domain. Taken together, these results establish the separate and linked CXXC domains of TET2 and TET3, respectively, as previously unknown regulators of caspase activation and TET enzymatic activity.
TET (ten-eleven-translocation) proteins are Fe(II)-and a-ketoglutarate-dependent dioxygenases [1] [2] [3] that modify the methylation status of DNA by successively oxidizing 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxycytosine 1, [3] [4] [5] , potential intermediates in the active erasure of DNA-methylation marks 5, 6 . Here we show that IDAX (also known as CXXC4), a reported inhibitor of Wnt signalling 7 that has been implicated in malignant renal cell carcinoma 8 and colonic villous adenoma 9 , regulates TET2 protein expression. IDAX was originally encoded within an ancestral TET2 gene that underwent a chromosomal gene inversion during evolution, thus separating the TET2 CXXC domain from the catalytic domain. The IDAX CXXC domain binds DNA sequences containing unmethylated CpG dinucleotides, localizes to promoters and CpG islands in genomic DNA and interacts directly with the catalytic domain of TET2. Unexpectedly, IDAX expression results in caspase activation and TET2 protein downregulation, in a manner that depends on DNA binding through the IDAX CXXC domain, suggesting that IDAX recruits TET2 to DNA before degradation. IDAX depletion prevents TET2 downregulation in differentiating mouse embryonic stem cells, and short hairpin RNA against IDAX increases TET2 protein expression in the human monocytic cell line U937. Notably, we find that the expression and activity of TET3 is also regulated through its CXXC domain. Taken together, these results establish the separate and linked CXXC domains of TET2 and TET3, respectively, as previously unknown regulators of caspase activation and TET enzymatic activity.
TET proteins are restricted to Metazoa and their presence is strictly correlated with the presence of cytosine methylation 2, 10 . Most animals have a single TET orthologue, characterized by an amino-terminal CXXC-type zinc finger domain and a carboxy-terminal catalytic Fe(II)-and a-ketoglutarate-dependent dioxygenase domain with an inserted cysteine-rich domain 2, 10 . In jawed vertebrates, the TET genes underwent triplication, and a subsequent chromosomal inversion split the TET2 gene into distinct segments encoding the catalytic and CXXC domains 2, 10 (Fig. 1a) . The ancestral CXXC domain of TET2 is now encoded by a distinct gene, IDAX, which is transcribed in the opposite direction ( Fig. 1b and Supplementary Fig. 1a ). Given the evolutionary relation between TET2 and IDAX, and the strong sequence conservation of IDAX across species ( Supplementary Fig. 1b ), we asked whether IDAX could influence the nuclear function of TET2.
We assessed the DNA-binding specificity of the IDAX CXXC domain. A glutathione S-transferase-tagged mouse IDAX CXXCdomain fusion protein (GST-IDAX(CXXC)) bound DNA oligonucleotides containing a single unmethylated CpG considerably more efficiently than oligonucleotides containing methylated CpG or no CpG (TpG), as also confirmed by competition with excess unlabelled oligonucleotides; the CFP1 CXXC domain, which preferentially binds DNA sequences containing unmethylated CpG 11 , was used as a control (Fig. 1c , left panel and Supplementary Fig. 2 ). The CXXC domain is found in several proteins involved in DNA methylation and chromatin modification [10] [11] [12] [13] [14] [15] [16] ( Supplementary Fig. 1c, d ). In the structures of the DNMT1-DNA complex and the MLL CXXC domain, short RSKQ and IKKQ loops mediate base-specific contacts with DNA containing unmethylated CpG dinucleotides 12, 13, 15 . These loops align with the RMKQ motif of KDM2A (also known as CXXC8) required for DNA binding 16 , the IRQ sequence of the CFP1 CXXC domain that is critical for recognition of unmethylated CpG 14 , and the TGHQ sequence in the IDAX CXXC domain ( Supplementary Fig. 1c ). We generated a homology model of the IDAX CXXC domain and showed that a TGHQ.AGAA substitution abrogated DNA binding (Fig. 1c , right panel and Supplementary Fig. 3 ). DNA tethering was required to maintain IDAX in the nucleus, as Myc epitope-tagged wild-type IDAX and TET2 were exclusively nuclear in HEK293T cells, whereas the IDAX DNA-binding mutant (IDAX DBM ) was partially present in the cytoplasm ( Supplementary Fig. 4) .
To determine the genomic distribution of IDAX, we used HEK293T cell lines stably expressing full-length Myc-IDAX or Myc-IDAX DBM ( Supplementary Fig. 5a ). Chromatin immunoprecipitation followed by next-generation sequencing identified 17,089 peaks for IDAX but only 38 peaks for IDAX DBM (Supplementary Tables 1, 2 ). Most of the IDAX peaks were located at promoters/transcription start sites (TSSs) and CpG islands (CGIs) of high CpG content (Fig. 1d-g , Supplementary Tables 1, 2 and Supplementary Fig. 5b, c) . IDAX-bound regions were enriched for sequences containing CG dinucleotides, tandem cytosines (as suggested previously for the TET3 CXXC domain 17 ) or both (Fig. 1h and Supplementary Table 3) , and were strongly associated with genes involved in messenger RNA splicing and transcriptional elongation ( Supplementary Fig. 5d , e). Thus IDAX preferentially associates with CpG-rich regions containing unmodified cytosines.
To find out whether IDAX and TET2 physically interact, we incubated GST-IDAX(CXXC) (Supplementary Fig. 2a ) with lysates from HEK293T cells expressing the TET2 catalytic domain (TET2 CD ) or the N-terminal region lacking the catalytic domain (TET2 DCD ) (Supplementary Fig. 6a, b) . The TET2 catalytic domain bound strongly to both the wild-type IDAX and IDAX DBM CXXC domain (Fig. 2a) , whereas TET2
DCD bound more weakly ( Supplementary Fig. 6c ). Coimmunoprecipitation assays confirmed a strong interaction between Myc-IDAX DBM (which does not downregulate TET2 protein; see below) and full-length TET2 or TET2 CD in HEK293T cells (Fig. 2b ). The interaction was direct, as Flag-tagged TET2 CD expressed in insect cells bound GST-IDAX(CXXC), but not GST-CFP1(CXXC), in pulldown assays ( Supplementary Fig. 6d, e) .
Unexpectedly, transient co-expression of Myc-IDAX and Flaghaemagglutinin-tagged TET2 in HEK293T cells led to the disappearance of TET2 protein and a decrease in 5-hydroxymethylcytosine (5hmC), with only a minor effect on TET2 mRNA ( Fig. 2c and Supplementary  Fig. 7 ). IDAX DNA-binding activity was required, as co-expressed Myc-IDAX DBM did not decrease TET2 protein or 5hmC (Fig. 2d , e and Supplementary Fig. 8 ). Myc-IDAX DBM was expressed at considerably higher levels than wild-type Myc-IDAX (Fig. 2d , e, g and Supplementary Fig. 8 ), suggesting that DNA-bound IDAX recruits a degradation complex that targets both IDAX and TET2 (see below, Supplementary Fig. 16 ). Treatment of cells co-expressing Myc-IDAX and Flag-HA-TET2 with proteasome inhibitors variably rescued the loss of TET2 protein, whereas treatment with lysosomal inhibitors had no effect ( Supplementary Fig. 9a, b) . However, IDAX was unable to decrease Myc-TET2 protein levels in cells treated with the pan-caspase inhibitor Z-VAD-FMK (Fig. 2f) ; moreover, wild-type IDAX induced nuclear cleavage of poly-(ADP-ribose) polymerase (PARP), a marker for caspase activation, whereas IDAX DBM did not ( Fig. 2g and Supplementary Fig. 9c ). TET2 was a direct target for caspase cleavage, as shown by treatment of HEK293T cell lysates containing Myc-TET2 with recombinant active human caspase 3 and caspase 8 ( Fig. 2h and Supplementary Fig. 9d, e) . Neither wild-type IDAX nor IDAX DBM influenced the enzymatic activity of TET2 in vitro ( Supplementary  Fig. 10 ), indicating that the loss of genomic 5hmC in cells co-expressing TET2 and IDAX reflects the loss of TET2 protein rather than any direct interference with TET2 enzymatic activity.
Regulation of TET2 by IDAX was observed in three independent systems. Idax mRNA levels were low in murine v6.5 embryonic stem cells (ESCs), but increased progressively upon leukaemia inhibitory factor (LIF) withdrawal and supplementation of the culture medium with retinoic acid (Fig. 3a, left panel) , concomitantly with decreased and increased expression of Tet1 and Tet3, respectively 18 ( Supplementary Fig. 11a ). Under these conditions, Tet2 mRNA levels were only slightly altered (Fig. 3a, right panel) , but TET2 protein levels decreased precipitously over a 3-day period ( Fig. 3b ; for TET2 antibody specificity see Supplementary Fig. 11b-d) . Lentiviral transduction of v6.5 ESCs with three effective short hairpin RNAs (shRNAs) against Idax (shIdax no. 1, 3 and 4; Fig. 3c ) substantially protected against the differentiation-induced downregulation of TET2 protein, whereas transduction with an ineffective shRNA, shIdax no. 2, did not (Fig. 3d) . Thus in differentiating murine ESCs, TET2 protein downregulation can be directly attributed to IDAX. In addition, transduction of the human U937 monocytic cell line, which barely expresses TET2, with four separate lentiviral shRNAs against IDAX resulted in strong TET2 protein expression (Fig. 3e) , suggesting that endogenous IDAX maintains low endogenous TET2 levels in U937 cells. Finally, IDAX expression, like TET2 deficiency 3, 19 , skewed the differentiation of murine bone marrow haematopoietic DBM in several respects: it was expressed at higher levels in HEK293T cells compared with wild-type or catalytically inactive TET3 (Fig. 4b, c) , a fraction of TET3 CXXC mut was aberrantly present in the cytoplasm (Fig. 4d , top panel) and TET3 CXXC mut was weaker than wild-type TET3 at inducing PARP cleavage in the nucleus (Fig. 4d , middle panel). Cells expressing TET3 CXXC mut displayed higher levels of genomic 5hmC compared with cells expressing wild-type TET3 (Fig. 4e ). This could not be attributed simply to increased protein levels of TET3 CXXC mut versus wild-type TET3, because the nuclear levels of these two proteins were comparable (Fig. 4d, top panel) . Together, these results indicate that TET3 autoregulates its protein levels via caspase activation, through a mechanism that requires DNA binding by the CXXC domain. The catalytic activity of TET3 may be controlled by an intramolecular interaction involving the CXXC domain (Fig. 4g) ; alternatively, the increased 5hmC in cells expressing TET3 CXXC mut could be due to loss of DNA tethering such that the mutant protein is more freely distributed than wild-type TET3 in the nucleus. By contrast, the expression and activity of TET1 CXXC mut were similar to those of wild-type TET1 ( Supplementary Fig. 13 ), suggesting that TET1 and TET3 are regulated by different mechanisms.
The IDAX-related protein CXXC5 (also known as RINF) is overexpressed in solid cancers and its high expression correlates with poor prognosis in breast cancer 20 . Notably, CXXC5 resembles IDAX in being a negative regulator of Wnt signalling 21 ; moreover, like TET2, CXXC5 has a role in normal myelopoiesis as well as in myeloid cancers and the CXXC5 gene is often deleted in myeloid leukaemias 22 . Like IDAX, mouse CXXC5 downregulated TET2 protein expression in a dose-dependent manner ( Fig. 4f and Supplementary Fig. 14) , suggesting that CXXC5 might also regulate the genomic localization, expression and enzymatic function of TET2.
We present a striking example of how a gene fission event, followed by a chromosomal inversion, facilitated the emergence of a previously unknown regulatory mechanism for DNA cytosine modification in vertebrates. The IDAX CXXC domain, which separated from the TET2 catalytic domain during vertebrate evolution 2, 10 , binds TET2 and potentially recruits it to promoters and CpG islands in genomic DNA. We propose that DNA-bound IDAX activates one or more caspases, perhaps at a transcriptional level through promoter/TSS binding ( Supplementary Fig. 15 ). Indeed, caspase 3 activation and IDAX upregulation occur with similar kinetics during ESC differentiation 23 .
As proposed for ubiquitylation 24 , caspase-mediated cleavage could be involved in the initial activation as well as the subsequent degradation of TET2 and IDAX ( Supplementary Fig. 16 ).
The cellular and subcellular distribution of IDAX, and its sensitivity to local environmental signals, may contribute to differences in 5hmC and TET2 levels in different cell types and organs 3, [25] [26] [27] . IDAX DBM is partly in the cytoplasm, and IDAX is reported to bind dishevelled in the cytoplasm in the absence of Wnt signalling 7 . Because IDAX is expressed at very low levels in ESCs but becomes upregulated upon differentiation, the genomic distribution of TET2 and oxidized methylcytosines in ESCs would be predicted to differ from those in LETTER RESEARCH more differentiated tissues, such as the primitive streak of the mouse embryo, in which Wnt signalling is prominent 28 . Further analyses will resolve these questions.
Many malignant tissues have been reported to contain low levels of 5hmC compared with normal tissues 29, 30 , and TET2 loss of function correlates with decreased 5hmC levels in patients with myeloid malignancies 3 . However, an appreciable proportion of patients with wild-type TET2 show low 5hmC 3 , suggesting the existence of additional factors that impair TET2 expression at the protein level and/or TET2 enzymatic activity. For instance, IDAX overexpression, reported in villous adenomas of the colon 9 , might promote TET2 degradation, leading to depletion of 5hmC in TET2 target genes. Conversely, the homozygous deletion of IDAX reported in an aggressive renal cell carcinoma 8 could result in TET2 overexpression and its aberrant recruitment to genomic regions where it is not normally found. It will be important in future studies to explore the genomic targets of TET2, IDAX and CXXC5 in normal development and cancer, and to define the effects of cancerassociated mutations in these proteins on patterns of cytosine modification in DNA.
METHODS SUMMARY
ChIP-seq and data analysis. Chromatin was prepared from two biological replicates of HEK293T cells expressing empty vector, Myc-IDAX or Myc-IDAX DBM using truChIP High Cell Chromatin Shearing Kit with Non-ionic Shearing Buffer (Covaris), sheared into 200-300 base-pair fragments using a Covaris S2 instrument as per manufacturer's instructions, and immunoprecipitated using anti-Myc conjugated to agarose (Sigma). Chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq) libraries were constructed using TruSeq Sample Prep kit (Illumina) and single-end sequencing was performed using Illumina HiSeq 2000. Sequencing reads were mapped against hg19 using Bowtie. Mapping results from both ChIP-seq experiments were combined and IDAX-enriched regions were identified by MACS peak-calling software. Cell cultures and lentiviral knockdown. For Idax and IDAX knockdown, the human monocytic U937 cell line or mouse v6.5 ESC cell line (cultured as described 18 ) were transduced with pLKO.1_Puro lentivirus expressing shRNA against Idax and IDAX, respectively (see Supplementary Table 4 for target sequences). Transduced cells were selected with puromycin. Lentivirus expressing shRNA against luciferase was used as a control. Author Information The ChIP-seq data have been deposited in the Gene Expression Omnibus (GEO) under accession number GSE42958. Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to A.R. (arao@liai.org).
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METHODS
Recombinant protein expression and purification. Competent BL21 cells were transformed with appropriate pGEX constructs, then induced to produce proteins using 100 ml Overnight Express Autoinduction System 2 (EMD Biosciences). Induced bacteria were collected and washed with 13 PBS. Next, cells were re-suspended in 15 ml PBS containing protease inhibitors (Roche) and lysed by sonication. The lysate was incubated in the presence of lysozyme (1 mg ml
21
) and Triton X-100 (1%) with gentle rotation for 30 min at 4 uC and hard spun at 20,000g for 30 min at 4 uC. The soluble fraction was incubated with 2 ml Glutathione Sepharose 4B slurry (HE Healthcare) with gentle rotation for 30 min at 4 uC and washed with cold 13 PBS three to four times. The recombinant GST fusion proteins were incubated in elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM reduced glutathione) for 10 min at 4 uC and the eluted proteins were collected by centrifugation. The elution and incubation steps were repeated three times to collect all proteins. Subsequently, the eluted protein was dialysed overnight in cold 13 PBS, 10% glycerol, 10 mM ZnCl 2 and 10 mM b-mercaptoethanol and flash frozen. Protein was concentrated by Amicon Ultra Spin columns 10,000 molecular weight cutoff. Protein expression and purification in Sf9 cells were described previously 1 . Integrity and purity of proteins were verified by SDS-PAGE and Coomassie blue staining, and purified protein was quantified using a Bradford assay. Electrophoretic mobility shift assay (EMSA). Single-stranded oligonucleotides used for substrate preparation were synthesized at IDT (Sequences in Supplementary Fig. 2b ). One nanomole of complementary single-stranded oligonucleotides was mixed in annealing buffer (10 mM Tris, pH 8.0, 50 mM NaCl, 1 mM EDTA), boiled for 4 min and gradually cooled overnight by transferring to a water bath preheated to 90 uC and turned off. The annealed oligonucleotides and singlestranded oligonucleotides as controls were separated by running on a 15% acrylamide gel in 0.53 Tris-borate-EDTA (TBE) gel. The gel was placed on an X-ray intensifying screen and irradiated with short-wave ultraviolet light to visualize DNA and excise the region of the gel containing the correct sized double-stranded oligonucleotides. The excised gel slice was crushed and incubated with 10 mM Tris, pH 8.0, 0.1 mM EDTA and 300 mM sodium acetate, pH 7.4, overnight at 37 uC with agitation. Supernatant was extracted, spun for 5 min at 14,000 r.p.m. to remove undissolved acrylamide, and the eluted DNA was purified by ethanol precipitation. A total of 100 ng double-stranded DNA was radiolabelled using T4 PNK enzyme (NEB) according to the manufacturer's protocols. Unincorporated ATP was removed using an illustra G-25 Micro Column (GE Healthcare). For the experiment shown in the left panel of Fig. 1c, 0 , 100, 200 and 400 ng of GST-IDAX CXXC domain was used. Except where otherwise noted, 500 ng of purified GSTtagged wild-type IDAX or IDAX DBM CXXC domain was incubated in a total of 20 ml reaction mixture containing 1 ng of radiolabelled oligonucleotide and 2 mg of poly(dA:dT), 20 mM HEPES, pH 7.9, 40 mM KCl, 2.5 mM MgCl 2 , 1 mM dithiothreitol (DTT) and 5% glycerol for 10 min on ice, then an additional 30 min at room temperature (,25 uC). For competition assays, the extracts were preincubated with unlabelled DNA competitors before addition of the reaction mixture. The resulting protein-DNA complexes were resolved in a non-denaturing 5% acrylamide gel in 0.53 TBE buffer. Gels were dried and visualized by autoradiography. Chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq). Chromatin was sheared using truChIP High Cell Chromatin Shearing Kit with Non-ionic Shearing Buffer (Covaris). In brief, cells were crosslinked with 13 Covaris fixing buffer at room temperature for 5 min with rotation, followed by addition of 13 Covaris quenching buffer. After further incubation at room temperature for 5 min with rotation, cells were washed with PBS twice at 4 uC and nuclei were prepared as per manufacturer's instructions. The nuclei pellet was re-suspended in 13 Covaris shearing buffer and chromatin was sheared into 200-300 base-pair (bp) fragments using a Covaris S2 instrument (duty cycle, 5%; intensity, 4; 200 cycles per burst; 20 min). Chromatin fragments from two biologically independent cells expressing empty vector, Myc-IDAX or Myc-IDAX DBM were immuneprecipitated using anti-Myc antibody conjugated to agarose (Sigma).
The ChIP-seq library was constructed using TruSeq Sample Prep kit (Illumina) and Illumina HiSeq sequencing was performed as per manufacturer's instructions. Data analyses. Sequencing reads were mapped against hg19 using Bowtie 31 (bowtie-0.12.7 -n 2 -l 28 -m 3 -k 1-best-chunkmbs 512 -p 8 -S -q) by suppressing all alignments for a particular read, if more than three reportable alignments exist, and by reporting only the best valid alignment per read. Mapping results from both ChIP-seq experiments per condition were combined and clonal reads (that is, reads mapped to the same genomic position) were replaced by one representative, resulting in 52.4 million, 43 million and 29.9 million reported reads for Myc-IDAX cells, Myc-IDAX DBM cells and cells expressing empty vector, respectively. Genomic regions enriched for short reads obtained from Myc-IDAX or Myc-IDAX DBM , respectively, were identified by using a local background estimated from short reads obtained from cells expressing empty vector using the statistical software MACS 32 . Annotation (hg19) of the obtained peaks was performed by using the annotatePeaks.pl function of the Homer software package 33 . The promoter region was defined as 21 kilobase (kb) to 10.1 kb relative to TSSs. In addition, we created Myc-IDAX-and Myc-IDAX DBM -specific peak sets by excluding all overlapping peaks. For the Myc-IDAX-specific peaks, we performed de novo motif discovery by using the findMotifsGenome.pl function of the Homer software package 33 using default parameter settings. Moreover, we calculated the CpG densities of the DNA sequences underlying the identified peaks, by the CpG observed/expected ratio ((number of CpG/(number of 3 number of G)) 3 total number of nucleotides in the sequence) 34 . In order to calculate immunoprecipitate enrichment at gene regions and at CpG islands, we accessed hg19 RefSeq gene annotations and CpG island annotations provided by the University of California Santa Cruz (UCSC) genome browser database (11/19/2012) 35 . According to their promoter CpG density, we divided all genes into low-CpG-density promoter (LCP) and high-CpG-density promoter (HCP) genes. For this, we calculated the CpG observed/expected ratio 34 of the sequences underlying the 21 kb to 10.5 kb region around their TSSs. By visual inspection of the CpG density distribution, we decided on a threshold of 0.44 for dividing the genes into LCP and HCP. In order to divide the CpG islands into high CpG (HCG)-, intermediate CpG (ICG)-and low CpG (LCG)-density islands, we calculated the CpG observed/expected ratio 34 of the underlying sequences. Subsequently, we sorted all CpG islands into five equally sized groups according to their descending CpG observed/expected ratio. We used the first, third and fifth group for defining HCG, ICG and LCG islands.
For the gene-centric enrichment analysis, each gene was divided into 20 bins. In addition, the 2-kb region upstream of the TSS, as well as the 2-kb region downstream of the transcription end site, was divided into 10 bins each. For the CpG island and TSS-centric analyses, we divided the 22 kb to 12 kb range around the midpoint of each island (or the TSS, respectively) into 80 bins. Short reads were extended to a length of 200 bp along their sequencing direction and bin-wise coverage was calculated using the Bioconductor 36 environment. In order to avoid division by zero, we added one to each bin of the immunoprecipitate and of the control sample. For each immunoprecipitate sample, a correction value for the library size was estimated by calculating the mean over the ratios of immunoprecipitate over control short-read coverage at genome-wide 100-bp windows. Subsequently, immunoprecipitate signals at the tested bins were divided by the correction value. Enrichment is defined by the log 2 of corrected immunoprecipitate signals divided by the control signals, where Myc-IDAX or Myc-IDAX DBM , respectively, is considered as immunoprecipitate and cells expressing empty vector is considered as control. For the average enrichment profiles, we calculate the log 2 of the mean over all corrected immunoprecipitate over control ratios at every tested position of stacked annotations. In-cell western blot. In-cell western was performed using standard immunocytochemistry procedures. Diluted DNA was mixed with 0.25 ml lipofectamine 2000 (Invitrogen) diluted in Opti-MEM reduced serum medium (Invitrogen) and incubated at room temperature for 20 min. HEK239T cells were trypsinized, washed and counted, and 2 3 10 4 cells were plated in each well of amine-coated BD PureCoat 384-well plate (BD Bioscience), followed by addition of the DNAlipofectamine mixture. Three days later, cells were fixed with 4% paraformaldehyde in PBS for 15 min and permeabilized with 0.2% Triton X-100 in PBS for 15 min at room temperature. Subsequently, DNAs were denatured with 2N HCl at room temperature for 30 min and neutralized with 100 mM Tris-HCl buffer, pH 8.5, for 10 min. Cells were incubated in Odyssey Blocking Buffer (LI-COR Biosciences) diluted 1:1 with PBS at room temperature for 1 h. Next, rabbit anti-5hmC polyclonal antibody (produced in-house; diluted to 1:2,500) for 5hmC staining or mouse anti-HA antibody (Covance, HA.11 clone 16B12, diluted to 1:1,000) and mouse anti-Myc antibody (Sigma, diluted to 1:2,000) for HA-TET2 and Myc-IDAX staining, respectively, were added into the blocking buffer for 3 h at room temperature. The cells were rinsed three times with 0.2% Triton X-100 in PBS and incubated at room temperature for 1 h with an IRDye 800CW-conjugated donkey anti-mouse IgG (1:4,000) or IRDye 680LT-conjugated donkey anti-rabbit IgG secondary antibody (1:1,000) (LI-COR Biosciences) in blocking buffer, and again washed four times with wash buffer, followed by addition of 50 ml PBS. Plates were scanned on the Odyssey Sa Infrared Imaging System and staining was quantified using the scanner software. To quantify cell density, cells were stained with IRDye 680LT maleimide (diluted into 10 ng ml 21 in PBS, LI-COR Biosciences) at room temperature for 15 min. After extensive washing with PBS three times, the plate was scanned again and staining was quantified using the scanner software. Western blotting and caspase-mediated TET2 cleavage in vitro. Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitor cocktail (Roche) or mixture of protease/phosphatase LETTER RESEARCH
